JPMorgan Chase & Co. Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price objective lowered by analysts at JPMorgan Chase & Co. from $35.00 to $33.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 31.58% from the company’s previous close.

Several other analysts have also weighed in on HIMS. Truist Financial reiterated a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Morgan Stanley decreased their target price on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Leerink Partners lifted their target price on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Citigroup reiterated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $29.50.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded down $4.06 on Tuesday, hitting $25.08. 27,985,094 shares of the company were exchanged, compared to its average volume of 33,140,680. The company’s 50 day moving average price is $23.08 and its two-hundred day moving average price is $29.44. Hims & Hers Health has a one year low of $13.74 and a one year high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 49.14, a PEG ratio of 3.85 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the previous year, the firm posted $0.20 EPS. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. Research analysts expect that Hims & Hers Health will post 0.53 earnings per share for the current year.

Insider Activity

In other Hims & Hers Health news, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider directly owned 8,752 shares in the company, valued at $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Chi sold 97,289 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer owned 407,282 shares in the company, valued at approximately $10,055,792.58. This trade represents a 19.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 204,857 shares of company stock valued at $5,285,706 in the last ninety days. 13.71% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Capital World Investors lifted its position in shares of Hims & Hers Health by 1.2% during the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after purchasing an additional 223,892 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State Street Corp lifted its position in shares of Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers raised its 2026 revenue outlook and also guided Q2 revenue above Wall Street estimates, suggesting management still sees solid demand ahead. Hims & Hers Health (NYSE:HIMS) Misses Q1 CY2026 Sales Expectations, Stock Drops 11.5%
• Positive Sentiment: Needham lifted its price target on HIMS to $35 from $30 and reiterated a Buy rating, signaling continued analyst confidence despite the weak quarter. Needham Raises Price Target on Hims & Hers Health
• Neutral Sentiment: BTIG reaffirmed a Neutral rating, reflecting a mixed near-term view as investors weigh growth against earnings volatility. BTIG Reaffirms Neutral Rating on Hims & Hers Health
• Neutral Sentiment: The company continues expanding its digital health platform with new care offerings, including labs, menopause, testosterone care, and international acquisitions, which supports the longer-term growth story. Hims & Hers Expands Digital Healthcare Platform via New Care Offerings
• Negative Sentiment: Q1 results showed a $92.1 million loss and a revenue miss, with management blaming the GLP-1 transition for higher costs and weaker margins. Hims & Hers plunges after weight-loss pivot hits quarterly results
• Negative Sentiment: The sharp sell-off reflects investor disappointment that the quarter did not meet expectations after a strong run-up in the share price. Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.